Literature DB >> 14688422

Corneal endothelial cytotoxicity of riboflavin/UVA treatment in vitro.

Gregor Wollensak1, Eberhard Spörl, Friedemann Reber, Lutz Pillunat, Richard Funk.   

Abstract

Recently, we have developed collagen crosslinking induced by combined riboflavin/UVA treatment, thus increasing the biomechanical rigidity of the cornea to treat progressive keratoconus. The present safety study was performed to evaluate possible cytotoxic effects of combined riboflavin/UVA treatment on the corneal endothelium in vitro. Endothelial cell cultures from porcine corneas were treated with 500 microM riboflavin solution, exposed to various endothelial UVA irradiances (370 nm) ranging from 0.1 to 1.6 mW/cm2 for 30 min and evaluated 24 h later using trypan blue staining and Yopro fluorescence staining. The effect of either treatment alone (UVA irradiation ranging from 0.2 to 6 mW/cm2) was also tested. An abrupt cytotoxic threshold irradiance level was found at 0.35 mW/cm2 after combined treatment with riboflavin plus UVA irradiation and at 4 mW/cm2 with UVA irradiation alone. Riboflavin alone was not toxic. A cytotoxic effect of the combined riboflavin/UVA treatment on corneal endothelial cells is to be expected with a corneal thickness of less than 400 microm. Therefore, pachymetry should be routinely performed before riboflavin/UVA treatment to exclude patients at risk. Copyright 2003 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14688422     DOI: 10.1159/000074071

Source DB:  PubMed          Journal:  Ophthalmic Res        ISSN: 0030-3747            Impact factor:   2.892


  55 in total

1.  [Corneal melting in both eyes after simultaneous corneal cross-linking in a patient with keratoconus and Down syndrome].

Authors:  C Faschinger; R Kleinert; A Wedrich
Journal:  Ophthalmologe       Date:  2010-10       Impact factor: 1.059

2.  Aliphatic β-nitroalcohols for therapeutic corneoscleral cross-linking: chemical stability studies using 1H-NMR spectroscopy.

Authors:  Xia Li; Yongjun Li; Mijung Kim; Stephen L Trokel; Nicholas J Turro; David C Paik
Journal:  Photochem Photobiol       Date:  2013-10-21       Impact factor: 3.421

3.  [Corneal crosslinking: "Safe and effective"?].

Authors:  C Cursiefen
Journal:  Ophthalmologe       Date:  2009-02       Impact factor: 1.059

Review 4.  Corneal collagen crosslinking in keratoconus and other eye disease.

Authors:  Adel Alhayek; Pei-Rong Lu
Journal:  Int J Ophthalmol       Date:  2015-04-18       Impact factor: 1.779

5.  Effects of ultraviolet-A and riboflavin on the interaction of collagen and proteoglycans during corneal cross-linking.

Authors:  Yuntao Zhang; Abigail H Conrad; Gary W Conrad
Journal:  J Biol Chem       Date:  2011-02-18       Impact factor: 5.157

Review 6.  Corneal collagen cross-linking using riboflavin and ultraviolet-A irradiation: a review of clinical and experimental studies.

Authors:  Maria Gkika; Georgios Labiris; Vassilios Kozobolis
Journal:  Int Ophthalmol       Date:  2011-08-17       Impact factor: 2.031

Review 7.  New clinical pathways for keratoconus.

Authors:  D M Gore; A J Shortt; B D Allan
Journal:  Eye (Lond)       Date:  2012-12-21       Impact factor: 3.775

8.  Biological and biomechanical responses to traditional epithelium-off and transepithelial riboflavin-UVA CXL techniques in rabbits.

Authors:  Brian K Armstrong; Michelle P Lin; Matthew R Ford; Marcony R Santhiago; Vivek Singh; Gregory H Grossman; Vandana Agrawal; Roy A Sinha; Robert S Butler; William J Dupps; Steven E Wilson
Journal:  J Refract Surg       Date:  2013-05       Impact factor: 3.573

Review 9.  Corneal collagen cross-linking for keratoconus and post-LASIK ectasia.

Authors:  Ronald N Gaster; Ana L Caiado Canedo; Yaron S Rabinowitz
Journal:  Int Ophthalmol Clin       Date:  2013

Review 10.  Corneal pain and experimental model development.

Authors:  Tina B McKay; Yashar Seyed-Razavi; Chiara E Ghezzi; Gabriela Dieckmann; Thomas J F Nieland; Dana M Cairns; Rachel E Pollard; Pedram Hamrah; David L Kaplan
Journal:  Prog Retin Eye Res       Date:  2018-11-16       Impact factor: 21.198

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.